Scinai Immunotherapeutics (SCNI) Share-based Compensation (2018 - 2026)

Scinai Immunotherapeutics (SCNI) has 9 years of Share-based Compensation data on file, last reported at $70000.0 in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation changed N/A year-over-year to $70000.0; the trailing twelve-month figure through Mar 2026 stood at $831000.0 (changed N/A YoY), and the FY2025 full-year result was $315000.0, down 66.91% from the prior year.
• Share-based Compensation declined to $70000.0 in Q1 2026, from $315000.0 in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $485000.0 in Q1 2022 to a low of $70000.0 in Q1 2026.
• A 5-year average of $271428.6 and a median of $243000.0 in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation sank 95.84% in 2022 and soared 86.92% in 2023, its largest moves.
• Tracing SCNI's Share-based Compensation over 5 years: stood at $398000.0 in 2022, then climbed by 13.82% to $453000.0 in 2023, then grew by 4.64% to $474000.0 in 2024, then plunged by 33.54% to $315000.0 in 2025, then plunged by 77.78% to $70000.0 in 2026.
• Business Quant data shows SCNI's Share-based Compensation at $70000.0 in Q1 2026, $315000.0 in Q4 2025, and $474000.0 in Q4 2024.